Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China
Crossref DOI link: https://doi.org/10.1007/s12325-022-02185-3
Published Online: 2022-05-29
Published Print: 2022-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Guan, Haijing
Wang, Chunping
Zhao, Zhigang
Han, Sheng http://orcid.org/0000-0001-5975-3574
Funding for this research was provided by:
National Natural Science Foundation of China (grant no. 72104151)
Text and Data Mining valid from 2022-05-29
Version of Record valid from 2022-05-29
Article History
Received: 24 March 2022
Accepted: 6 May 2022
First Online: 29 May 2022